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Abstract
Background: The slow Wallerian Degeneration (WldS) gene specifically protects axonal and synaptic
compartments of neurons from a wide variety of degeneration-inducing stimuli, including; traumatic injury,
Parkinson's disease, demyelinating neuropathies, some forms of motor neuron disease and global cerebral
ischemia. The WldS gene encodes a novel Ube4b-Nmnat1 chimeric protein (WldS protein) that is
responsible for conferring the neuroprotective phenotype. How the chimeric WldS protein confers
neuroprotection remains controversial, but several studies have shown that expression in neurons in vivo
and in vitro modifies key cellular pathways, including; NAD biosynthesis, ubiquitination, the mitochondrial
proteome, cell cycle status and cell stress. Whether similar changes are induced in non-neuronal tissue
and organs at a basal level in vivo remains to be determined. This may be of particular importance for the
development and application of neuroprotective therapeutic strategies based around WldS-mediated
pathways designed for use in human patients.
Results: We have undertaken a detailed analysis of non-neuronal WldS expression in WldS mice, alongside
gravimetric and histological analyses, to examine the influence of WldS expression in non-neuronal tissues.
We show that expression of WldS RNA and protein are not restricted to neuronal tissue, but that the
relative RNA and protein expression levels rarely correlate in these non-neuronal tissues. We show that
WldS mice have normal body weight and growth characteristics as well as gravimetrically and histologically
normal organs, regardless of WldS protein levels. Finally, we demonstrate that previously reported WldS-
induced changes in cell cycle and cell stress status are neuronal-specific, not recapitulated in non-neuronal
tissues at a basal level.
Conclusions: We conclude that expression of WldS protein has no adverse effects on non-neuronal
tissue at a basal level in vivo, supporting the possibility of its safe use in future therapeutic strategies
targeting axonal and/or synaptic compartments in patients with neurodegenerative disease. Future
experiments determining whether WldS protein can modify responses to injury in non-neuronal tissue are
now required.
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Background
Degeneration of axonal and/or synaptic compartments of
neurons is an early and pathologically important process
in many disorders of the human nervous system, ranging
from Alzheimer's disease and Batten disease through to
multiple sclerosis and motor neuron disease [1-8]. Thera-
pies designed to specifically delay or halt the progression
of axonal and synaptic degeneration are therefore actively
being sought for a wide range of neurological disorders.
The most robust delay in axonal and synaptic degenera-
tion reported to date in animal models of neurological
disorders has been generated by the introduction of the
slow Wallerian degeneration (WldS) gene. To date, the
WldS gene has been shown to significantly modify disease
onset and/or progression in animal models of traumatic
axonal injury [9,10], Parkinson's disease [11,12], demy-
elinating neuropathies [13], some forms of motor neuron
disease [14] and cerebral ischemia [15]. These experi-
ments highlight the potential for using the WldS protein
and/or its downstream molecular interactions to generate
novel therapeutic approaches for the treatment of neuro-
logical disorders. Importantly, the ability to successfully
deliver the WldS gene and confer robust neuroprotection
using gene therapy approaches [16,17] has opened up the
possibility of directly delivering WldS-related therapies to
human patients.
The chimeric WldS gene occurred as the result of a sponta-
neous mutation in the C57BL/6 line of mice (originally
termed C57BL/6/Ola [9]), resulting in a tandem triplica-
tion of a region already present on the distal region of
chromosome 4. Mice carrying the WldS mutation are oth-
erwise indistinguishable from their C57BL/6J strain mates
in genotyping of more than 50 microsatellite markers and
restriction fragment length polymorphisms (RFLPs [18-
20]). The triplicated region contains sequences coding for
Nmnat1, Rbp7 and Ube4b [21]. The boundaries within
the triplicated region result in 2 copies of a fusion gene
comprising the N70 terminal amino acids of Ube4b and
the entire coding region of Nmnat1 (C Terminal 285
amino acids), linked by 18 amino acids from the 5'
untranslated region of Nmnat1 which are not normally
expressed [18,21,22]. The chimeric portion of the triplica-
tion (i.e. the N-70 Ube4b/Nmnat1 C-303 chimera) has
been shown to be sufficient to recapitulate the WldS phe-
notype through the generation of transgenic lines in mice,
rats and drosophila [23-25].
Although the WldS gene has obvious therapeutic poten-
tial, its mechanism of action remains unclear. However,
several studies have shown that expression of WldS pro-
tein in neurons in vivo and in vitro induces changes in core
cellular pathways, including; NAD biosynthesis, ubiquiti-
nation, the mitochondrial proteome, cell cycle status and
cell stress [17,26-28]. Even though the extent to which
each of these modifications contribute to the neuropro-
tective phenotype remains unclear, the fact that WldS
modifies key cellular pathways raises potential problems
for its use as a therapeutic agent that have yet to be inves-
tigated. For example, it is conceivable that changes in
NAD biosynthesis pathways and/or cell cycle pathways in
non-neuronal organs and tissues may alter their form
and/or function.
Here, we have undertaken the first detailed study of the
effects of WldS expression in non-neuronal tissues in vivo.
We show that WldS protein is expressed at differing levels
in a range of non-neuronal organs in WldS mice. Systemic
expression of WldS did not affect overall body weight or
growth. Gravimetric and histological analysis of a wide
range of organs and tissues confirmed no changes in WldS
mice. We also demonstrate that previously reported alter-
ations in cell cycle and cell stress proteins reported in WldS
brain tissue are a neuronal-specific response not observed
in non-neuronal organs in vivo.
Results
WldS expression is not limited to neuronal tissue in vivo
Despite numerous reports in the literature concerning the
therapeutic potential of the WldS gene (see background
above), no previous studies have undertaken a rigorous
assessment of the consequences of WldS expression in
non-neuronal tissue. We first examined the expression of
WldS protein and RNA levels in a variety of organs from
WldS mice and wild-type controls and compared expres-
sion levels to those observed in the cerebellum [29,30].
Organs examined included liver, kidney, heart, lung and
spleen. We used quantitative fluorescent western blotting
techniques to assess and compare protein expression lev-
els using a proven antibody for the WldS protein (Wld-18
antibody [23,30,31]; Figure 1). Example bands are shown
in Figure 1A for liver (which had little to no WldS protein
expression), spleen (intermediate levels of expression)
and the cerebellum (strong expression).
These experiments showed that WldS protein expression
was not limited to neuronal tissue, but that it was not
strongly expressed in all organs examined (Figure 1B). For
example, the liver had the lowest expression at 0.06 ± 0.09
(mean ± SEM) fold increase compared to wild-type back-
ground signal, the spleen showed a 6.27 ± 1.05 fold
increase, whereas the cerebellum showed a 17.82 ± 0.96
fold increase. We also examined RNA expression in WldS
mice (Figure 1C) and found that RNA expression varied
greatly between different organs and did not necessarily
correlate with protein expression. For example, the liver
(which showed the lowest protein expression of the
organs examined) had relatively high RNA expression lev-
els, approaching those observed in the cerebellum. TakenBMC Neuroscience 2009, 10:148 http://www.biomedcentral.com/1471-2202/10/148
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together, these findings demonstrate that WldS protein
and RNA are present in a range of non-neuronal organs at
differing levels, but also demonstrate that the presence of
RNA does not always indicate that WldS protein will also
be present at comparable levels.
The observation that WldS protein is strongly expressed in
non-neuronal tissues led us to investigate whether there
would be sufficient protein in tail tips to facilitate accurate
genotyping of WldS  mice using western blotting. We
found that quantitative western blotting techniques easily
distinguished between wild-type, heterozygous and
homozygous WldS mice (Figure 2).
Systemic expression of WldS did not affect gross 
appearance or growth rates
In order to test whether systemic WldS expression affected
total body weight, mice were bred from parents hetero-
Expression of WldS protein and mRNA in non-neuronal tis- sue Figure 1
Expression of WldS protein and mRNA in non-neuro-
nal tissue. A - Representative examples of bands obtained 
with quantitative fluorescent western blots from wild-type 
and WldS mouse liver, spleen and cerebellum probed with 
antibodies against WldS protein (Wld-18) and beta-actin 
(loading control). B - WldS protein levels in organs from WldS 
mice expressed as fold change in protein relative to wild-type 
tissue. Note that all organs except for the liver showed sig-
nificant levels of WldS protein, but none to the same magni-
tude as found in the cerebellum. C - WldS RNA levels in 
organs from WldS mice shown as relative expression normal-
ised to wild-type. Note that RNA levels did not always match 
protein expression levels (c.f. Panel A). A minimum of 3 mice 
per genotype were used for all experiments.
WldS mice can be accurately genotyped by quantitative west- ern blots of tail tip protein expression Figure 2
WldS mice can be accurately genotyped by quantita-
tive western blots of tail tip protein expression. Tail 
tips were homogenized in RIPA buffer and following a BCA 
assay, 30 μg of protein were loaded per lane of a pre-cast 
gradient gel (see methods section). A - Representative exam-
ple bands obtained with quantitative fluorescent western 
blots from a litter of mice produced by a heterozygous 
breeding pair. The litter contained wild-type, heterozygous 
and homozygous WldS mice. Blots were probed for WldS 
protein levels using the Wld18 antibody. Tubulin was used as 
a loading control (data not shown). B - WldS protein expres-
sion shown as arbitrary fluorescence units, illustrating that 
protein expression was roughly doubled in homozygous mice 
compared to heterozygous mice. N = 4 wild-type mice, N = 
3 heterozygous WldS mice and N = 5 homozygous WldS mice.BMC Neuroscience 2009, 10:148 http://www.biomedcentral.com/1471-2202/10/148
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zygous for the WldS mutation (see methods). Litters from
this heterozygote cross contained mice which were null
for WldS (WT), mice which were heterozygous for WldS
(Het) and mice which were homozygous for WldS (WldS).
All experimental comparisons were carried out within lit-
ters to remove any potential effects of background strain.
There were no obvious qualitative differences in the size
or behaviour of mice within litters. Figure 3A shows 5
female mice from the same experimental litter (contain-
ing a mixture of WT, Het and WldS mice), indistinguisha-
ble from one another. Mice were weighed at regular
intervals post weaning up to 2 months of age. There were
no significant differences between the body weights of
WT, Het and WldS mice at any time-point examined (P >
0.2, ANOVA; Figure 3B; Het data not shown; N = 7 WT, N
= 5 WldS).
WldS expression did not affect gravimetrics or 
histopathology of non-neuronal tissue
Detailed necropsies were carried out by an experienced
rodent pathologist (DGB) on WT, Het and WldS litterma-
tes to determine if non-neuronal expression of WldS pro-
tein had any affects on tissue gravimetrics (Table 1) or
histopathology (Figure 4). Organs examined for gravimet-
rics included kidneys, liver, spleen, thymus, heart and
whole brain. In order to minimize the effects of natural
biological variability within litters data were expressed as
organ weight per grams/body weight. No significant dif-
ferences were observed between mice from any of the 3
genotypes (Table 1). Mice were also examined for altera-
tions in body fat deposits (interscapular, pelvic, subcuta-
neous and mesenteric), with no evident differences (data
not shown).
Histopathological assessments were carried out on the fol-
lowing organs and tissues: kidney, heart, lungs, mediasti-
num, liver, gallbladder, urinary bladder, vagina, uterus,
ovary, spleen, pancreas, lymph nodes, salivary gland, pitu-
itary gland, adrenal gland, stomach, intestines (6 levels),
calvarial bone, femur, tibia, knee joint, spine and spinal
cord (4 levels, transverse sections), eyes, head, various
sympathetic and parasympathetic ganglia, brain (trans-
verse sections at 250 μm intervals). No significant differ-
ences were observed between any of the genotypes.
Example sections for comparison are shown in Figure 4.
Figure 4A shows representative images of liver from wild-
type and WldS mice, a tissue with little to no detectable
WldS protein expression (see Figure 1). Note the presence
of normal hepatocyte nuclei, sinusoids and central veins
in both images. Figure 4B shows representative images of
kidney cortex, a tissue with intermediate levels of WldS
protein expression, showing the presence of normal
glomeruli, Bowman's capsules and cortical tubular pro-
files. Figure 4C shows representative images of spleen, a
tissue with high WldS protein expression, with normal red
pulp and white pulp lymphoid accumulations.
Cell cycle and cell stress alterations are specific to 
neuronal tissue
We have previously reported alterations in proteins
involved with cell cycle and cell stress in non-injured neu-
ral tissue from WldS mice in vivo and in vitro [26,27]. In
order to determine whether similar changes were insti-
gated in non-neuronal organs and tissues expressing WldS
protein we examined expression levels of the cell stress
marker antiphosphohistone H2Ax (H2Ax) and a marker
of cell cycle progression acetylated histone H3 (H3) in
liver, kidney, heart, lung, spleen and cerebellum from
wild-type and WldS mice. Example bands for both of these
proteins are shown in Figure 5A. As previously demon-
strated there was a significant (P < 0.001; unpaired t-test)
increase in expression of both cell stress and cell cycle
markers in WldS cerebellum compared to wild-type (Fig-
ure 5). However, no changes in expression of either of
these proteins were found in any of the non-neuronal
organs examined (Figure 5). Thus, previously reported dif-
Systemic expression of WldS does not affect gross appear- ance or growth rates of mice Figure 3
Systemic expression of WldS does not affect gross 
appearance or growth rates of mice. A - Photograph of 
2 month old female mice from a representative litter pro-
duced by heterozygous WldS breeding pairs. This litter con-
tains wild-type, heterozygous and homozygous WldS mice. 
There was no obvious gross difference in size, appearance or 
behaviour. B - Line graph showing body weight plotted 
against mouse age in days for wild-type (grey line) and WldS 
(black line) mice. No significant differences were observed 
between genotypes at any time-point examined (Anova). N = 
7 wild-type, N = 5 WldS.BMC Neuroscience 2009, 10:148 http://www.biomedcentral.com/1471-2202/10/148
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ferences in cell cycle and cell stress status appear to be a
neuronal-specific response to expression of WldS at a basal
level.
Discussion
Here we have shown that WldS  RNA and protein are
expressed at differing levels in a range of non-neuronal
organs in WldS mice but did not influence overall body
weight or growth. Gravimetric and histological analysis of
a wide range of organs demonstrated that the presence of
WldS RNA and/or protein had no overt influence on non-
neuronal tissues at a basal level. We have also shown that
previously reported alterations in cell cycle and cell stress
proteins reported in WldS brain tissue are neuronal-spe-
cific and are not observed in non-neuronal organs in vivo.
It will now be of interest to establish whether WldS protein
can modify responses to injury in non-neuronal tissues
and organs, where it is expressed. Expression data in the
current study show that the spleen has a comparatively
high level of protein, suggesting that this organ may be
useful for such studies.
These data demonstrate that downstream consequences
of  WldS  expression, incorporating pathways including
NAD biosynthesis, ubiquitination, the mitochondrial
proteome, cell cycle status and cell stress [17,26-28], do
not have any major adverse effects on non-neuronal
organs. This suggests that the utilization of WldS-based
therapeutics for treating neurodegenerative conditions
can be considered safe for other body systems, should the
treatment spread beyond the confines of the nervous sys-
tem (e.g. unintentionally or as a result of systemic admin-
istration). Studies reporting that WldS-mediated
neuroprotection (as well as many of its downstream effec-
tors such as Nmnat pathways) can be successfully deliv-
ered to the nervous system using approaches such as viral
gene delivery suggest that WldS-based therapeutics are a
realistic possibility [16,17].
Our experimental data have also revealed nervous system-
specific effects of WldS expression. The finding that modi-
fications in cell cycle and cell stress status previously
reported in neurons expressing WldS [27] are not repli-
cated in non-neuronal tissues suggests that neurons may
have distinct intrinsic responses to the presence of WldS.
One possible explanation for this is that neurons are ter-
minally differentiated cells whose cell cycle status is mark-
edly different from many non-neuronal cells (for review
see [32]). Whether or not this contributes directly to the
neuroprotective phenotype remains to be determined.
Nevertheless, these data support the hypothesis that WldS
acts by targeting a specific step(s) in degenerative path-
ways intrinsic to neurons [33].
Table 1: WldS protein expression did not affect gravimetrics of non-neuronal organs (bwt: body-weight)
WT Mean WT SEM WldS Mean WldS SEM t test
Bwt (g) 25.46 1.39 23.56 1.61 ns
Kidneys (g/bwt) 14.20 2.23 17.37 0.62 ns
Liver (g/bwt) 62.16 1.66 57.06 2.51 ns
Spleen (g/bwt) 3.73 0.25 4.24 0.44 ns
Thymus (g/bwt) 3.03 0.34 3.66 0.35 ns
Heart (g/bwt) 6.59 0.33 6.63 0.32 ns
Brain (g/bwt) 20.65 1.36 21.08 0.86 ns
WldS protein expression did not affect histopathology of  non-neuronal organs Figure 4
WldS protein expression did not affect histopathol-
ogy of non-neuronal organs. H & E staining of tissues 
showed no obvious qualitative differences between wild type 
(left), heterozygous (data not shown) or homozygous WldS 
mice (right) for liver (A), kidney (B), and spleen (C). The 
selected organs shown represent non-neuronal organs with 
low (liver), medium (kidney) and high (spleen) levels of WldS 
protein expression. Scale bar = 100 μm (A&B), 200 μm (C).BMC Neuroscience 2009, 10:148 http://www.biomedcentral.com/1471-2202/10/148
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Conclusions
We conclude that expression of WldS  protein has no
adverse effects on non-neuronal tissue at a basal level in
vivo, supporting the possibility of its safe use in future
therapeutic strategies targeting axonal and/or synaptic
compartments in patients with neurodegenerative dis-
ease.
Methods
Mouse breeding
Natural mutant C57Bl6/WldS (WldS) mice and C57Bl/6
(wild-type) mice were obtained from Harlan Olac Labora-
tories (Bicester, UK) and housed within the animal care
facilities in Edinburgh. All animal experiments were car-
ried out in accordance with the guidance and rules of, and
under license from, the UK Home Office. Breeding pairs
made up of one WldS mouse and one wild-type mouse
were used to generate heterozygous WldS mice. These mice
were then bred to produce litters which contained mice
null for the WldS mutation (wild-type), mice heterozygous
for the mutation (Het) and mice homozygous for the
mutation (WldS). All data were obtained from tissue har-
vested from 1-2 month old mice. For body weight meas-
urements, mice were weighed every 2 days post weaning.
A minimum of 3 mice were used per group for all experi-
ments.
Genotyping
Mice were bred as detailed above, ear-notched and
assigned individual identifying numbers which were used
so the experimenter remained blind to the genotype of
individual mice throughout. Mice were genotyped post
mortem and their genetic status was only assigned after
data collection and analysis was complete. Mice were ini-
tially genotyped by quantitative western blotting for WldS
protein expression levels using protein extracted from tail
tips using similar methodology described below (see Fig-
ure 2). These genotypes were all validated by real-time
PCR as previously described [34].
Necropsy
Mice were killed with carbon dioxide gas and immediately
weighed. Selected organs were weighed and a standard
panel of organs were immersion-fixed in 10% neutral-
buffered formalin for histopathology. Fixed organs were
embedded in paraffin, sectioned at 4 mm, and stained
with hematoxylin and eosin. All analyses were undertaken
with the investigator blind to the genotype of each ani-
mal.
RNA extraction & qRT-PCR
Cerebellum, liver, spleen, thymus, lung, and heart from 6-
week-old female WldS mice were flash frozen on dry ice
and mRNA was extracted using the RNAEasy Kit (Qiagen,
Valencia, CA). Messenger RNA from all tissues was trans-
formed into cDNA using the Superscript III kit (Invitro-
gen, Carlsbad, CA). Quantitative real-time PCR (qRT-
PCR) was performed to examine WldS gene expression
using a Sybr-Green '1-step qRT-PCR kit' (Invitrogen) on
an ABI PRISM 7700 Instrument (Applied Biosystems, Fos-
ter City, CA). The following primer sequences were used:
WldS-726F TGTGCCCAAGGTGAAATTGC
Cell cycle and cell stress pathway alterations were specific to  neuronal tissue Figure 5
Cell cycle and cell stress pathway alterations were 
specific to neuronal tissue. A - Representative examples 
of bands obtained from quantitative fluorescent western 
blots from wild-type and WldS mouse spleen and cerebellum 
probed with antibodies against cell stress (H2Ax) and cell 
cycle (H3) proteins (beta actin is shown as a loading control). 
Spleen was chosen because it had the highest WldS protein 
expression levels of all the non-neuronal tissues examined 
(Figure 1). Note the increases in H2Ax and H3 in WldS cere-
bellum compared to wild-type mice, but no change in the 
expression of either protein in the spleen. B - Bar chart 
showing cell cycle (H3) and cell stress (H2Ax) protein levels 
in a range of organs from WldS mice expressed as fold change 
in protein relative to wild-type. Both proteins examined 
showed only very minor fluctuations in expression levels in 
non-neuronal tissue (left hand side of dotted line). The mag-
nitude of change in non-neuronal tissue did not begin to 
approach those observed in the cerebellum of WldS mice 
(right hand side of dotted line). A minimum of 3 mice per 
genotype were used for each experiment.BMC Neuroscience 2009, 10:148 http://www.biomedcentral.com/1471-2202/10/148
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WldS-818R ACGATTTGCGTGATGTCCTCC
β-actin was used as a control gene. To verify that there was
minimal genomic DNA contamination, we also per-
formed qRT-PCR analysis of selected extracted mRNA
samples prior to conversion to cDNA, which demon-
strated a negligible genomic DNA presence (10,000×
less).
Protein extraction & quantitative western blotting
Mice were killed by cervical dislocation and organs for
examination rapidly removed. Protein was extracted from
tail tips, cerebella and organs including the kidney, liver,
heart, lung and spleen of age- and sex-matched mice in
RIPA buffer with 10% protease inhibitor cocktail (Sigma)
as previously described [26,27]. 30 μg of protein per lane
was separated by SDS/Polyacrylamide gel electrophoresis
on 4-20% pre-cast NuPage 4-12% Bis Tris gradient gels
(Invitrogen) and then transferred to PVDF membrane
overnight. The membranes were then blocked using
Odyssey blocking buffer (Li-COR) and incubated with
primary antibodies as per manufacturers instructions
(anti acetyl Histone H3 - Lake Placid Biologicals;
antiphosphohistone H2Ax - Upstate; anti beta actin and
anti beta-III-tubulin - Abcam). Wld-18 antibodies were a
kind gift from Dr Michael Coleman and were used as pre-
viously described [30]. Odyssey secondary antibodies
were added according to manufacturers instructions
(Goat anti rabbit IRDye 680 and Goat anti mouse IRDye
800). Blots were imaged using an Odyssey Infrared Imag-
ing System (Li-COR Biosciences). Scan resolution of the
instrument ranges from 21-339 μm and in this study blots
were imaged at 169 μm. Quantification was performed on
single channels with the Li-COR analysis software pro-
vided, as previously described [26,27].
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